Glaxo Wellcome Australia Limited v Boiron

Glaxo Wellcome Australia Limited (Glaxo) brought proceedings against Boiron, a French pharmaceutical company, in the Federal Court of Australia. The dispute concerned the alleged infringement of Glaxo's Australian trade mark registration for the word mark "ZANTAC" for pharmaceutical preparations. Glaxo sought an injunction to restrain Boiron from using the mark "ZANTAC" in Australia, and damages for the alleged infringement.

The primary legal issue before the Court was whether Boiron's use of the trade mark "ZANTAC" in relation to its homeopathic preparations constituted an infringement of Glaxo's registered trade mark. This involved determining whether the goods in respect of which Boiron used the mark were of the same description or description for which Glaxo's mark was registered, and whether such use was likely to deceive or cause confusion.

Justice Terry Williams found that the goods were not of the same description. He reasoned that while both parties' products were pharmaceutical preparations, the nature and intended use of homeopathic preparations were fundamentally different from those of conventional pharmaceutical preparations like Glaxo's ranitidine-based product. The Court applied the principles of trade mark infringement, focusing on the likelihood of deception or confusion, and concluded that consumers would not be confused into believing that Boiron's homeopathic products were associated with or endorsed by Glaxo.

Consequently, the Court dismissed Glaxo's claim for trade mark infringement.